Login
Immunovant, Inc. logo

Immunovant, Inc.

immunovant.com

What Do They Do?

Develops an antibody drug candidate to treat autoimmune diseases driven by harmful antibodies.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q2 FY2027, the three months to Sep 30, 2026
Net income
▲ +23% (Loss)
vs −$126.5M in Q2 FY2026

Narrower development focus The older report described development of both antibody candidates; the latest report says Immunovant discontinued development of its first candidate across indications and is focusing on the other.

Who Do They Compete With?

Competes with Argenx, Johnson & Johnson, UCB, Viridian Therapeutics, AstraZeneca, Amgen, Sanofi, Dianthus, Crinetics Pharmaceuticals, Lycia Therapeutics, Biohaven, Merida Biosciences, Yarrow Bioscience, Biogen, and Merck

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support